3 uniQure Directors Each Sell 1,993 Shares; Stock Now $27.57

For biotech investors, insider transactions at pre‑revenue gene therapy companies carry heightened significance. When multiple directors at uniQure simultaneously sell identical share lots just three months after a major analyst upgrade, it prompts a closer look at whether the rally in QURE stock is built on pipeline potential or short‑term price momentum. This cluster of insider selling serves as a real‑world case study in reading the tea leaves of biotech insider activity.

On June 11, 2026, three non-executive directors of gene therapy company uniQure N.V. (NASDAQ: QURE) — Jack Kaye, Madhavan Balachandran, and David Meek — each sold precisely 1,993 shares of company stock at $27.06 per share, yielding proceeds of $53,930.58 apiece. The simultaneous and identical lot sizes raise questions about whether these were pre‑arranged sales under Rule 10b5‑1 trading plans or a coordinated lightening of insider holdings. Combined, the directors unloaded $161,791.74 worth of stock, trimming their positions by 4% to 7%. While such insider selling is not uncommon, particularly after a sharp recovery in share price, the optics in a pre‑revenue biotech with a heavy cash burn deserve scrutiny.

“

At $27.57, the stock sits well above its 50‑day moving average of $22.31 and its 200‑day MA of $21.76, reflecting a sharp rebound from the 52‑week low of $8.73.

uniQure pioneered the first FDA‑approved gene therapy for hemophilia B (Hemgenix, licensed in 2022), but commercial uptake has been slow, and the company continues to report steep losses. In the most recent quarter reported on May 5, 2026, uniQure posted revenue of only $3.56 million, missing the consensus estimate of $5.21 million, albeit with a slight beat on EPS (‑$0.85 vs. ‑$0.88 expected). The quarterly loss underscores the ongoing challenge of converting its one‑time curative therapy into a sustainable revenue stream. With a negative return on equity of 145.81% and a net margin deep in negative territory, the company relies on its cash position and ability to raise capital. At $27.57, the stock sits well above its 50‑day moving average of $22.31 and its 200‑day MA of $21.76, reflecting a sharp rebound from the 52‑week low of $8.73. However, it remains far from the 52‑week high of $71.50, suggesting that the gene therapy narrative has lost some of its pandemic‑era froth.

The recent insider sales occur just one day after the stock rose $0.75 on Friday, June 12, to close at $27.57 on light volume (about one‑third of the average). The market’s reaction to the insider filing was muted, possibly because the sales were small relative to the directors’ overall holdings — Kaye’s stake remains valued at over $700,000, Balachandran’s at $1.17 million, and Meek’s at $1.08 million. Moreover, institutional investors have been adding to positions: Woodline Partners boosted its stake by 25% in the first quarter, and Jones Financial Companies increased its holdings by 509% in the third quarter, signaling that some professional money managers see value.

The insider selling comes just three months after RBC Capital upgraded uniQure from “sector perform” to “outperform” and lifted its price target from $11 to $35 on March 9, 2026. That upgrade appeared to ignite a rally, as the stock had been languishing near $11. The upgrade cited optimism around the company’s pipeline, particularly AMT‑130 for Huntington’s disease, which is in Phase I/II trials. For biotech investors, insider selling following a strong analyst upgrade can be a yellow flag: directors may be taking the opportunity to monetize shares when the stock price is elevated, possibly indicating that they do not share the analyst’s enthusiasm.